141 related articles for article (PubMed ID: 5292808)
1. The biochemistry of catecholamines in relation to Parkinson's disease.
Hinterberger H
Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
[No Abstract] [Full Text] [Related]
2. Catecholamine metabolism during oral administration of levodopa.
Hinterberger H; Andrews CJ
Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
[No Abstract] [Full Text] [Related]
3. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
[No Abstract] [Full Text] [Related]
4. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
Routh JI; Bannow RE; Fincham RW; Stoll JL
Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
[No Abstract] [Full Text] [Related]
5. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
Jones DG; Turnbull MJ; Lenman JA; Robertson MA
J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
[No Abstract] [Full Text] [Related]
6. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
Jequier E; Dufresne JJ
Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
[No Abstract] [Full Text] [Related]
7. The metabolic fate of levodopa in man and animals.
Louis WJ; Doyle AE; Sampson RG
Clin Exp Pharmacol Physiol; 1974; 1(4):341-6. PubMed ID: 4459002
[No Abstract] [Full Text] [Related]
8. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
[No Abstract] [Full Text] [Related]
9. Catecholamines in Parkinson's disease.
Rinne UK; Sonninen V
Acta Neurol Scand; 1970; 46(S43):217-8. PubMed ID: 5457829
[No Abstract] [Full Text] [Related]
10. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
Uono M; Tanabe H; Yano Y; Nakao K
No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
[No Abstract] [Full Text] [Related]
11. [Catecholamine metabolism in the tissue of malignant and benign tumors of the sympathetic nervous system].
Käser H; Türler K; Burri PH
Schweiz Med Wochenschr; 1971 Apr; 101(13):484-7. PubMed ID: 5558918
[No Abstract] [Full Text] [Related]
12. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
13. [Biochemistry and treatment of Parkinson's disease].
Barbeau A
Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
[No Abstract] [Full Text] [Related]
14. [Effect of veloergometric exercise to the limit of endurance on indices of the sympatho-adrenal system in subjects with different degrees of physical training].
Men'shikov VV; Bol'shakova TD; Erez VP; Lukicheva TI; Dubobes GK
Probl Endokrinol (Mosk); 1973; 19(1):45-51. PubMed ID: 4698455
[No Abstract] [Full Text] [Related]
15. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
Jones DG; Lenman JA; Robertson MA; Turnbull MJ
Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
[No Abstract] [Full Text] [Related]
16. Development of a screening test for L-dopa and its metabolites in urine.
Routh JI; Bannow RE
Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
[No Abstract] [Full Text] [Related]
17. [Catecholamine excretion in children with neurogenic tumors of the mediastinum].
Stepanov EA; Bukhny AE; Bol'shakova TD; Lukicheva TI
Khirurgiia (Mosk); 1972 Jun; 48(6):125-8. PubMed ID: 5043043
[No Abstract] [Full Text] [Related]
18. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
[No Abstract] [Full Text] [Related]
19. Metabolism and clinical assessment of L-dopa in parkinsonism.
Ericsson AD; McCann D; Sharpless N; Reveno W
Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
[No Abstract] [Full Text] [Related]
20. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
